
- Mount Sinai Doctors
- Treats Adults
- Video Visit Available
- Accepting New Patients
Yelena Z Ginzburg, MD
Internal Medicine, Hematology-Oncology
About Me
Yelena Ginzburg, MD, is Associate Professor (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai. She sees patients with a wide range of benign hematologic diseases and malignant diseases such as myeloproliferative neoplasms (MPNs) at the Ruttenberg Treatment Center at The Mount Sinai Hospital, with a focus on individualized, patient-centered care.
Dr. Ginzburg conducts research on erythropoiesis and iron metabolism; she aims to understand how exploiting these pathways can be translated into developing therapeutics and improving care in multiple diseases.
Dr. Ginzburg mentors graduate students from the Graduate School of Biomedical Sciences, postdoctoral fellows, and clinical residents and fellows at the Icahn School of Medicine at Mount Sinai and other institutions, with a productive record of clinical and basic research publications.
Prior to joining Mount Sinai in 2016, Dr. Ginzburg served as Medical Director for Medical Programs/Services and the Cell Therapy Laboratory and Donor Center Medical Director at the New York Blood Center in addition to developing her own laboratory research program in the Erythropoiesis Laboratory. She recently served on the Board of Directors of the International BioIron Society and is the current chair of the East-West-Iron-Club. Dr. Ginzburg sits on the American Society of Hematology Committee on Iron and Heme, and reviews grants and publications for government and private entities.
Language
English
Position
PROFESSOR | Medicine, Hematology and Medical Oncology
Hospital Affiliations
- Mount Sinai Queens
- The Mount Sinai Hospital
Research Topics
Apoptosis/Cell Death, Cellular Differentiation, Hematopoiesis, Iron Metabolism, Molecular Biology, Transgenic Mice
Multi-Disciplinary Training Areas
Cancer Biology [CAB], Development Regeneration and Stem Cells [DRS]
Download the CVClinical Focus
- Hematologic Malignancies
Education
MD, Sackler School of Medicine (Tel Aviv University)
Residency, Internal Medicine
Montefiore Medical Center
Residency, Internal Medicine
Montefiore Medical Center-Moses Division
Fellowship, Hematology & Oncology
Montefiore Medical Center
Fellowship, Hematology & Oncology
Montefiore Medical Center
Certifications
American Board of Internal Medicine
Research
Another main interest of the laboratory is to understand the regulation of erythrocyte differentiation and survival. Epo binding to Epo receptor triggers a complicated and incompletely understood set of potentially related molecular signals influencing cell survival, differentiation, and enucleation. Although Epo is associated with increased survival of erythroid precursors, it induces reactive oxygen species (ROS), and high Epo concentration has an anti-enucleation effect in vitro [Zhao Exp Hematol 2016]. Furthermore, diseases of ineffective erythropoiesis, e.g. β-thalassemia, are associated with increased Epo and ROS concentrations implicated in the expansion of and damage to erythroid precursors, respectively. Treating erythroblasts with low dose ROS scavenger promotes enucleation, but high dose ROS scavenger leads to cell death [Zhao Exp Hematol 2016], suggesting that an optimal ROS concentration is integral to effective erythropoiesis. We and others have shown that ROS is increased in β-thalassemic erythroid precursors, but despite increased ROS, erythroid precursor apoptosis is not increased. We hypothesize that compensatory mechanisms prevent the ill-effects of increased ROS on erythroid precursors. Our prior experiments demonstrate disordered erythropoiesis in β-thalassemic (th1/th1) mice, restored in transferrin-treated th1/th1 mice [Liu Blood 2013], despite which, ROS remained increased in erythroid precursor from transferrin-treated th1/th1 mice. To identify mechanisms responsible for transferrin’s effect, we performed RNA seq analysis of erythroblasts from wild type (WT), th1/th1, and transferrin-treated th1/th1 mice. We identified increased pleckstrin-2 (plek2) in th1/th1 relative to WT mice, normalized in transferrin-treated th1/th1 mice. We hypothesize that plek2 activation counteracts the ill effects of ROS and promotes enucleation in β-thalassemia. Another currently funded collaborative R01 is aimed at exploring the role of plek2 in erythroid differentiation and enucleation in β-thalassemia (R01 NIDDK; PI: Ji).
Please visit the Ginzburg Laboratory.
Insurance Information
Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.
- 1199 SEIU
- AETNA - Commercial
- AETNA - Medicare
- Affinity Medicaid-Medicare-Essential Exchange
- Amidacare Medicaid
- CIGNA Healthcare
- Centivo
- Elderplan
- EmblemHealth - GHI-PPO
- EmblemHealth - HIP
- EmblemHealth - HIP-Medicaid
- EmblemHealth - HIP-Medicare
- Empire Blue Cross Blue Shield - Commercial/Exchange
- Empire Blue Cross Blue Shield - HealthPlus Medicaid
- Empire Blue Cross Blue Shield - Medicare
- Fidelis Health Care
- HealthFirst Medicaid
- HealthFirst Medicare
- Horizon NJ
- Magnacare-Health Care
- Medicare - NJ
- Medicare - NY
- Metroplus
- Multiplan PHCS
- NJ Medicaid
- NY Medicaid
- Oscar
- Oxford - Freedom and Liberty
- Partners Health Plan
- Senior Whole Health
- United Health Care - Commercial
- United Health Care - Empire Plan
- United Health Care - Oxford Care
- United Health Care - Top Tier
- VNSNY Choice Medicare
- VNSNY Select Health Medicaid
- VillageCareMax
- WellCare Health Plan
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
Publications
Selected Publications
- Iron-Loading Anemias. Maayan V. Levy, Yelena Z. Ginzburg.
- Oral Decitabine/Cedazuridine Is an Effective Ambulatory Therapy for Patients With Myelofibrosis Refractory to JAK2 Inhibitor Therapy. Shivani Handa, Ganesh Sivakumar, Andrew Srisuwananukorn, Amylou Dueck, Douglas Tremblay, John O. Mascarenhas, Yelena Ginzburg, Marina Kremyanskaya, Ronald Hoffman. Clinical Lymphoma, Myeloma and Leukemia
- Mitoxantrone ameliorates ineffective erythropoiesis in a β-thalassemia intermedia mouse model. Haihang Zhang, Rui Liu, Zheng Fang, Ling Nie, Yanlin Ma, Fei Sun, Jingjing Mei, Zhiyin Song, Yelena Z. Ginzburg, Jing Liu, Huiyong Chen. Blood advances
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Dr. Ginzburg has not yet completed reporting of Industry relationships.
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.